ERLONAT

Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:

  • Non-small cell lung cancer (NSCLC).
    • It is used as first-line treatment for metastatic NSCLC in patients with tumors that have certain epidermal growth factor receptor (EGFR) mutations.
    • It is used for locally advanced or metastatic NSCLC in patients who have already been treated with chemotherapy.
  • Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.
ErlonatERLONAT
AVAILABLE AS:
100,150MG tablets. (30 Tab Bottle )
MANUFACTURE BY:
NATCO (INDIA)

 

Recommended Dose:
Oral
Locally advanced or metastatic non-small cell lung carcinoma
Adult: 150 mg once daily until disease progression or unacceptable toxicity. Reduce dose in decrements of 50 mg when necessary.
Oral
Locally advanced, unresectable or metastatic pancreatic cancer
Adult: As 1st-line treatment with gemcitabine: 100 mg once daily, reduce dose in decrements of 50 mg when necessary.

Consult your doctor for proper Dosage for yourself